M. M. Chan and C. S. Lam, How do patients with heart failure with preserved ejection fraction die?, Eur J Heart Fail, vol.15, pp.604-613, 2013.

J. Butler, G. C. Fonarow, M. R. Zile, C. S. Lam, L. Roessig et al.,

O. Chioncel, S. P. Collins, P. Dunnmon, G. Filippatos, M. P. Lefkowitz et al.,

M. Gheorghiade, Developing Therapies for Heart Failure With Preserved Ejection Fraction: Current State and Future Directions, JACC Heart Fail, vol.2, pp.97-112, 2014.

P. Ponikowski, A. A. Voors, S. D. Anker, H. Bueno, J. Cleland et al.,

E. A. Jankowska, M. Jessup, C. Linde, P. Nihoyannopoulos, J. T. Parissis et al.,

F. Rutten, F. H. Van-der-meer, and P. , ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, Eur J Heart Fail, vol.18, pp.891-975, 2016.

L. H. Lund, D. E. Oger, E. Hage, C. Persson, H. Haugen-lofman et al.,

J. C. Daubert and C. Linde, Association between cardiovascular vs. non-cardiovascular co-morbidities and outcomes in heart failure with preserved ejection fraction, Eur J Heart Fail, vol.16, pp.992-1001, 2014.

C. S. Lam and L. H. Lund, Microvascular endothelial dysfunction in heart failure with preserved ejection fraction, Heart, vol.102, pp.257-259, 2016.

W. J. Paulus and C. Tschope, A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation, J Am Coll Cardiol, vol.62, pp.263-271, 2013.

C. Hage, E. Michaelsson, C. Linde, D. E. Daubert, J. C. Gan et al., Inflammatory Biomarkers Predict Heart Failure Severity and Prognosis in Patients With Heart Failure With Preserved Ejection Fraction: A Holistic Proteomic Approach, Circ Cardiovasc Genet, vol.10, issue.1, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01446558

E. Donal, L. H. Lund, E. Oger, C. Hage, H. Persson et al.,

J. C. Daubert and C. Linde, Baseline characteristics of patients with heart failure and preserved ejection fraction included in the Karolinska Rennes (KaRen) study, Arch Cardiovasc Dis, vol.107, pp.112-121, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01147020

Y. Oh, S. R. Nagalla, Y. Yamanaka, H. S. Kim, E. Wilson et al., Synthesis and characterization of insulin-like growth factor-binding protein (IGFBP)-7. Recombinant human mac25 protein specifically binds IGF-I and-II, J Biol Chem, vol.271, pp.30322-30325, 1996.

V. Evdokimova, C. E. Tognon, T. Benatar, W. Yang, K. Krutikov et al., IGFBP7 binds to the IGF1 receptor and blocks its activation by insulin-like growth factors, Sci Signal, vol.5, p.92, 2012.

M. Joshi, S. R. Kotha, S. Malireddy, V. Selvaraju, A. R. Satoskar et al.,

, Conundrum of pathogenesis of diabetic cardiomyopathy: role of vascular endothelial dysfunction, reactive oxygen species, and mitochondria, Mol Cell Biochem, vol.386, pp.233-249, 2014.

P. U. Gandhi, H. K. Gaggin, M. M. Redfield, H. H. Chen, S. R. Stevens et al.,

, Like Growth Factor-Binding Protein-7 as a Biomarker of Diastolic Dysfunction and Functional Capacity in Heart Failure With Preserved Ejection Fraction: Results From the RELAX Trial, JACC Heart Fail, vol.4, pp.860-869, 2016.

P. U. Gandhi, H. K. Gaggin, A. D. Sheftel, A. M. Belcher, R. B. Weiner et al., Prognostic usefulness of insulin-like growth factor-binding protein 7 in heart failure with reduced ejection fraction: a novel biomarker of myocardial diastolic function?, Am J Cardiol, vol.114, pp.1543-1549, 2014.

S. Chugh, M. Ouzounian, Z. Lu, M. S. Li, W. Bousette et al., Pilot study identifying myosin heavy chain 7, desmin, insulin-like growth factor 7, and annexin A2 as circulating biomarkers of human heart failure, Proteomics, vol.13, pp.2324-2334, 2013.

P. U. Gandhi, S. L. Chow, T. S. Rector, H. Krum, H. K. Gaggin et al., Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction, J Card Fail, vol.23, pp.20-28, 2017.

S. R. Motiwala, J. Szymonifka, A. Belcher, R. B. Weiner, A. L. Baggish et al., Measurement of novel biomarkers to predict chronic heart failure outcomes and left ventricular remodeling, J Cardiovasc Transl Res, vol.7, pp.250-261, 2014.

E. Donal, L. H. Lund, C. Linde, M. Edner, S. Lafitte et al.,

Y. , L. D. Derumeaux, G. Gueret, P. Daubert, and J. C. , Rationale and design of the Karolinska-Rennes (KaRen) prospective study of dyssynchrony in heart failure with preserved ejection fraction, Eur J Heart Fail, vol.11, pp.198-204, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00911681

U. L. Faxen, C. Hage, L. Benson, S. Zabarovskaja, A. Andreasson et al.,

H. Hfpef, Display Different Phenotypes as Assessed by IGF-1 and IGFBP-1, J Card Fail, vol.23, pp.293-303, 1017.

U. L. Faxen, C. Hage, A. Andreasson, D. E. Daubert, J. C. Linde et al., HFpEF and HFrEF exhibit different phenotypes as assessed by leptin and adiponectin, Int J Cardiol, vol.228, pp.709-716, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01446565

M. C. Barroso, F. Kramer, S. J. Greene, D. Scheyer, T. Kohler et al., Serum insulin-like growth factor-1 and its binding protein-7: potential novel biomarkers for heart failure with preserved ejection fraction, BMC Cardiovasc Disord, vol.16, p.199, 2016.

M. Schanz, J. Shi, C. Wasser, M. D. Alscher, M. Kimmel et al., TIMP-2] x [IGFBP7] for risk prediction of acute kidney injury in decompensated heart failure, Clin Cardiol, vol.40, pp.485-491, 2017.

Y. Liu, M. Wu, J. Ling, L. Cai, D. Zhang et al., Serum IGFBP7 levels associate with insulin resistance and the risk of metabolic syndrome in a Chinese population, Sci Rep, vol.5, p.10227, 2015.

A. Shaver, A. Nichols, E. Thompson, A. Mallick, K. Payne et al., Role of
URL : https://hal.archives-ouvertes.fr/hal-00356231

, Serum Biomarkers in Early Detection of Diabetic Cardiomyopathy in the West Virginian Population, Int J Med Sci, vol.13, pp.161-168, 2016.

A. Zeidan and M. Karmazyn, Leptin and vascular smooth muscle, Curr Vasc Pharmacol, vol.4, pp.383-393, 2006.

T. Usui, T. Murai, T. Tanaka, K. Yamaguchi, D. Nagakubo et al.,

, Characterization of mac25/angiomodulin expression by high endothelial venule cells in lymphoid tissues and its identification as an inducible marker for activated endothelial cells, Int Immunol, vol.14, pp.1273-1282, 2002.

E. Komiya, M. Furuya, N. Watanabe, Y. Miyagi, S. Higashi et al., Elevated expression of angiomodulin (AGM/IGFBP-rP1) in tumor stroma and its roles in fibroblast activation, Cancer Sci, vol.103, pp.691-699, 2012.

H. J. Verhagen, D. C. De-leeuw, M. G. Roemer, F. Denkers, W. Pouwels et al.,

G. J. Smit and L. , IGFBP7 induces apoptosis of acute myeloid leukemia cells and synergizes with chemotherapy in suppression of leukemia cell survival, Cell Death Dis, vol.5, p.1300, 2014.

B. Pitt, M. A. Pfeffer, S. F. Assmann, R. Boineau, I. S. Anand et al.,

B. Harty, J. F. Heitner, C. T. Kenwood, E. F. Lewis, E. O'meara et al.,

S. Yang and S. M. Mckinlay, Spironolactone for heart failure with preserved ejection fraction, N Engl J Med, vol.370, pp.1383-1392, 2014.

B. M. Massie, P. E. Carson, J. J. Mcmurray, M. Komajda, R. Mckelvie et al.,

C. and P. A. , Irbesartan in patients with heart failure and preserved ejection fraction, N Engl J Med, vol.359, pp.2456-2467, 2008.

. Copeptin, , vol.14, p.28

, Suppression of Tumorigenicity 2 (ng/mL) 23 (16;30) 35 (23;51)

, Galectin-3 (ng/mL) 17 (13, vol.21, p.17

. Table, Baseline characteristics in the 22 LVAD and 34 HTx patients. Continuous variables are presented as median and interquartile range (lower and upper quartiles; Q1;Q3) and categorical variables as numbers (n) and % when not otherwise stated